Germany

German politicians counter AstraZeneca vaccine scepticism with show of support

  • by

Oxford Covid vaccine described in German media as ‘shelf warmer’ with only 17% of doses administered so far Coronavirus – latest updates See all our coronavirus coverage Politicians in Germany are stepping out in support of the AstraZeneca vaccine as public scepticism around the Oxford-developed… Read More »German politicians counter AstraZeneca vaccine scepticism with show of support

Assessing the impact of prevalence on pricing of rare disease drugs in Germany

  • by

In this first article of a three-part series exploring pricing in Europe, CRA’s Life Sciences Practice team discuss the role that disease rarity plays in reimbursement decisions among payers in Germany. Historically, payers have accepted factors including small target patient populations and high clinical development… Read More »Assessing the impact of prevalence on pricing of rare disease drugs in Germany

German government challenges AstraZeneca Covid vaccine efficacy reports

  • by

Newspaper had reported that government was expecting European regulator’s assessment to show that vaccine was only 8% effective among over-65 The German government has challenged reports of a lower-than-expected efficacy rate of the AstraZeneca vaccine for older people, while reiterating concerns about the British-Swedish pharmaceutical… Read More »German government challenges AstraZeneca Covid vaccine efficacy reports

BioNTech’s Covid vaccine is a triumph of innovation and immigration | Hans-Werner Sinn

  • by

Pioneered by a Turkish-German couple, its significance exceeds its practical value The world took note when the German startup BioNTech announced its breakthrough in the development of a new type of vaccine to combat Covid-19. After testing tens of thousands of people, BioNTech’s vaccine has… Read More »BioNTech’s Covid vaccine is a triumph of innovation and immigration | Hans-Werner Sinn

Pfizer and BioNTech Elicits Strong T-cell Response in P-I/II Study Against COVID-19

  • by

Shots: The companies reported that most advanced of four COVID-19 vaccine candidates from their BNT162 mRNA-based vaccine program demonstrated the ability to elicit high SARS-CoV-2 neutralizing titers following the second dose in an ongoing P-I/II study in Germany The results divulge that BNT162b1 candidate induced… Read More »Pfizer and BioNTech Elicits Strong T-cell Response in P-I/II Study Against COVID-19